The FDA's Cancer Drug Advisory Panel Has Lost Its Acting Chair and Carries Multiple Vacancies

What Changed on the CommitteeThe panel of outside experts the FDA turns to on cancer drugs has lost its acting chair and now has several empty seats. The Oncologic Drugs Advisory Committee is, in the words of the cancer research organization Friends of Cancer Research, the panel "responsible for making recommendations concerning development and approval of cancer drugs." The confirmed facts are that the committee's acting chair has departed at the end of a four-year term and that multiple seats are reported open. The FDA's Oncologic Drugs Advisory Committee, a panel of outside experts that makes non-binding recommendations on cancer drug development and approval. Neil Vasan of NYU departed as acting chair at the end of a four-year term.